

Regulation of Off-Label Drugs Warrants Attention

BY JOYCE FRIEDEN
Senior Editor

PHILADELPHIA — The Food and Drug Administration needs to change the way it regulates promotion of off-label drug use, according to the chair of the department of health policy and public health at the University of the Sciences in Philadelphia.

This year, the FDA issued draft guidance regarding off-label promotion. The draft

guidance states that although any materials promoting off-label use must be peer reviewed, approval by the agency is not required, and the pharmaceutical company does not need to prove its intent to submit a new drug application for the off-label use, Robert I. Field, J.D., Ph.D., said at a meeting of the American Society of Law, Medicine, and Ethics. "This is considered to be a significant loosening of the requirements, certainly of the FDA's enforcement attitude."

However, the company must clearly disclose that the suggested use is off-label, and any published negative findings regarding the off-label use must be included in the materials. "The problem is, negative findings don't get published very often, so there's probably not going to be a whole lot of that," he added.

The comment period on the FDA's draft guidance ended several months ago; final guidance has yet to be issued. But there are certainly reasonable arguments for pro-

moting off-label use under certain circumstances, according to Dr. Field.

Medicine only advances when information is shared, "and there are good reasons to allow off-label uses and therefore to allow physicians to know about those off-label uses," he said. "On the other hand, it is clear that lack of oversight will lead to overzealous, aggressive promotion of uses that have limited, if any, scientific substantiation. The big question [is whether the] average physician, who's working 80 hours a week [is] really going to be able to evaluate this information, even if it has a disclosure written at the top?"

Although the ultimate goal should be to get approval for an off-label use, pharmaceutical companies don't have many good reasons to do so, Dr. Field noted. "The problem is that clinical trials take a lot of time and the FDA is an overburdened agency; its reviews are slow." Off-label use is abundant and has grown over the last 3 decades, Dr. Field said.

Before 1997, the FDA opposed all off-label promotion. The agency allowed limited distribution of peer-reviewed articles in direct response to physician requests.

In 1997, Congress passed the Food and Drug Administration Modernization Act, which allowed pharmaceutical companies to initiate distribution of articles promoting off-label use if they came from a legitimate peer-reviewed source, such as a journal or book chapter, and they could sponsor continuing medical education if it was done through a third-party operation.

But there were restrictions on these uses—the material to be distributed first had to be given to the FDA for approval, and the company had to intend to submit a new drug application for the off-label use.

In 1998, the Washington Legal Foundation sued the FDA, arguing that the restrictions on article distribution were unconstitutional under the First Amendment. The court said the agency could limit article distribution but could not require prior submission of the materials for FDA approval or require that the company intend to submit a new drug application. A similar lawsuit in 1999 produced the same result.

These rulings "left questions as to what would and wouldn't be allowed" under the act, Dr. Field said. Other challenges to off-label promotion rules were not as successful. In 2004, Pfizer Inc. was fined \$430 million for paying physicians to promote the off-label use of gabapentin (Neurontin) with little evidence of benefit. And a psychiatrist was arrested in 2006 for accepting \$100,000 to promote off-label uses for Jazz Pharmaceutical Inc.'s sodium oxybate (Xyrem).

REGISTER NOW: WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM

Rheumatology News® AND  SKIN DISEASE EDUCATION FOUNDATION PRESENT

EARN UP TO
11 Credits
of CME

A continuing medical education conference

PERSPECTIVES IN RHEUMATIC DISEASES: MEETING THE CLINICAL CHALLENGE

DECEMBER 6-7, 2008 • HILTON FORT LAUDERDALE BEACH RESORT • FORT LAUDERDALE, FLORIDA

CHAIR

Daniel E. Furst, MD

Carl M. Pearson Professor of Medicine
Department of Medicine, Division of Rheumatology
David Geffen School of Medicine at the University
of California, Los Angeles (UCLA)

CO-CHAIR

Kenneth B. Gordon, MD

Head, Division of Dermatology
Evanston Northwestern Healthcare
Northwestern University Feinberg
School of Medicine, Chicago



CLINICAL HIGHLIGHTS

- **Autoimmunity Unbound: New Insights Into the Pathogenesis of Rheumatoid Arthritis**
Daniel E. Furst, MD
- **What's Ahead: New Therapies for the Treatment of Rheumatoid Arthritis**
Tore K. Kvien, University of Oslo, Past President EULAR 2005-2007
- **New Frontiers: Therapeutic Options in Juvenile Idiopathic Arthritis**
Charles H. Spencer, MD, Nationwide Children's Hospital/Ohio State University
- **MRI in Rheumatology**
Norman B. Gaylis, MD, Private Practice, University of Miami
- **Assessing Cardiac Complications in Connective Tissue Diseases**
David Edmundowicz, MD, University of Pittsburgh Medical Center
- **New Advances in the Treatment Options in SLE**
Susan Manzi, MD, MPH, University of Pittsburgh School of Medicine
- **Autoimmune Threats to Kidney Function**
Jonathan Ashley Jefferson, MD, MRCP, University of Washington
- **Clinical Manifestations and Complications of Systemic Scleroderma**
Daniel E. Furst, MD
- **Gout: What's Ahead in Disease Management**
Robert L. Wortmann, MD, Dartmouth-Hitchcock Medical Center
- **New Paradigms in Managing and Treating Ankylosing Spondylitis**
Tore K. Kvien, University of Oslo, Past President EULAR 2005-2007
- **Crohn's Disease and Ulcerative Colitis: Challenges of Inflammatory Bowel Disease**
Sunanda V. Kane, MD, Mayo Clinic College of Medicine
- **Panel Discussion: Collaborative Care of Patients with Immunologic-Based Diseases: A Rheumatology/Dermatology Perspective**
Daniel E. Furst, MD, Moderator, Kenneth B. Gordon, MD, Christopher T. Ritchlin, MD

DERMATOLOGY ESSENTIALS FOR THE RHEUMATOLOGIST

- **More Than Skin Deep: Understanding and Managing the Patient With Psoriasis**
Kenneth B. Gordon, MD
- **Therapeutic Advances in the Treatment of Psoriatic Arthritis**
Christopher T. Ritchlin, MD, University of Rochester School of Medicine and Dentistry
- **Rashes, Erythema, and Spots: Common Skin Disorders**
Michael D. Tharp, MD, Rush University Medical Center
- **Weird and Worrisome: Uncommon Skin Diseases**
Francisco Kerdel, MD, University of Miami

PROGRAM OVERVIEW

New treatment modalities are being developed in rheumatology based on scientific research breakthroughs in immunology, cytokines, T lymphocytes, B lymphocytes, as well as genetic studies that may result in gene therapies. Rheumatologists and other health care professionals need comprehensive knowledge of the latest developments and techniques in diagnosing and treating rheumatic disorders to ensure the highest standards of patient care. Rheumatologists need to have an understanding of dermatologic co-morbidities that often appear in their patients.

*Program subject to change.

Supported, in part,
by educational grants from  centocor and  AMGEN  Wyeth

TUITION	Early Bird	After 10/6/2008
Physicians	\$450	\$495
Residents/NPs/PAs	\$300	\$325

ACCOMMODATIONS

Hilton Fort Lauderdale Beach Resort
Fort Lauderdale, Florida

1 (954) 414-2222: Mention *Rheumatology News Perspectives in Rheumatic Diseases* group to receive the special rate of \$239 plus tax.

TARGET AUDIENCE

This continuing medical education conference is designed for rheumatologists, nurse practitioners, and physician assistants.

LEARNING OBJECTIVES

At the conclusion of this conference, participants will be able to:

- Identify the recent advances in the diagnosis, management, and treatment of rheumatic diseases
- Discuss the link between rheumatoid arthritis and inflammatory bowel diseases
- Apply the most current information concerning the pathophysiology of rheumatic disorders to patient care plans
- Recognize and differentiate common as well as rare skin diseases relevant to rheumatic diseases

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin Disease Education Foundation (SDEF). The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

AMA PRA CREDIT DESIGNATION STATEMENT

The EOCME designates this educational activity for a maximum of 11 *AMA PRA Category 1 Credit(s)*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Jointly sponsored by



WWW.RHEUMATOLOGYNEWSPERSPECTIVES.COM | PHONE: (973) 290-8200 | FAX: (973) 290-8250